Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A photographer helps his mom get cured of hep C after reading Hep magazine.
Maviret and Vosevi were highly effective and well tolerated in clinical trials.
The triple-drug combo would be the first once-daily, single-tablet regimen for those with all genotypes who’ve failed a previous treatment.
Gilead has tested the addition of the investigational voxilaprevir to its already approved Epclusa (sofosbuvir/velpatasvir).
Information about Epclusa, the newest treatment for chronic hepatitis C virus infection.
The FDA has granted priority review status to Gilead’s application for approval of a once-daily combo tablet of Sovaldi and velpatasvir.
What new therapies are the major players in hepatitis C pharmaceuticals developing?
The FDA has granted priority review status to Gilead investigational pangenotypic HCV fixed-dose combination tablet, Sovaldi/velpatasvir.
In a couple of weeks, the FDA is expected to rule on Merck’s new hepatitis C treatment for genotypes 1,4, and 6.
Elizabeth Faraone, now cured of hepatitis C, discusses treatment and the power of advocacy
Sovaldi and velpatasvir, with/without ribavirin, yielded good results among people with various genotypes of HCV and decompensated cirrhosis
Gilead Sciences Sovaldi (sofosbuvir) and velpatasvir posted near-perfect results in curing an array of genotypes of hepatitis C.
Selecting my favorite hepatitis C research presented at the recent annual liver meeting
Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of hep C
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.